Developing a Blood Cell-Based Diagnostic Test for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Using Peripheral Blood Mononuclear Cells. — CFSMEATLAS
Developing a Blood Cell-Based Diagnostic Test for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Using Peripheral Blood Mononuclear Cells.
Xu, Jiabao, Lodge, Tiffany, Kingdon, Caroline et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023 · DOI
Quick Summary
Researchers used a new technology called Raman spectroscopy combined with artificial intelligence to analyze blood cells from ME/CFS patients and healthy people. The test was able to correctly identify ME/CFS patients about 91% of the time and could even distinguish between mild, moderate, and severe cases with 84% accuracy. This could eventually help doctors diagnose ME/CFS with a simple blood test instead of relying only on patient symptoms.
Why It Matters
ME/CFS lacks objective diagnostic biomarkers, forcing many patients to pursue years of testing before diagnosis. A validated blood-based test could reduce diagnostic delays, improve clinical management, and enable better patient stratification for research and treatment trials. The methodology may also be applicable to other unexplained post-infectious conditions like long COVID.
Observed Findings
Raman spectral profiles of blood cells differentiated ME/CFS patients from healthy controls with 91% accuracy.
The same technology distinguished mild, moderate, and severe ME/CFS cases with 84% accuracy.
Specific Raman peaks were identified that correlate with ME/CFS phenotypes and disease severity.
Disease control participants were successfully distinguished from both ME/CFS patients and healthy controls.
The analysis revealed potential biochemical markers in blood cells associated with ME/CFS.
Inferred Conclusions
Single-cell Raman spectroscopy combined with AI can identify objective blood-based signatures of ME/CFS with clinically promising accuracy.
Blood cell spectral profiles reflect disease severity and could potentially support disease stratification and monitoring.
This technology may provide insights into the biological mechanisms underlying ME/CFS and guide therapeutic development.
Remaining Questions
Will these Raman signatures remain stable over time, and can they be used to monitor disease progression or response to treatment?
How do these blood cell changes relate to the underlying pathophysiology of ME/CFS—are they primary causes or secondary effects?
What This Study Does Not Prove
This study does not establish causation—it identifies correlations between blood cell spectral profiles and ME/CFS status. The cross-sectional design cannot determine whether observed cellular changes cause ME/CFS or result from it. The findings require independent validation in larger, prospectively-designed studies before this test can be used clinically.